Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noboru Yamamoto

Showing results (71-80 of 437) with videos related to

Pageof 44
Sort By:
Investigational New Drugs|July 2, 2016
Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumorsHidenori Mizugaki, Noboru Yamamoto, Haruyasu Murakami, et al.
Japanese Journal of Clinical Oncology|October 22, 2014
A Phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small-cell lung cancer (JCOG1201)Junko Eba, Tsuneo Shimokawa, Kenichi Nakamura, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|September 20, 2020
The optimal duration of antimicrobial therapy for lower respiratory tract infection in patients with neuromuscular disorders based on a clone library analysis of the bacterial 16S rRNA gene sequenceMasaru Kawamura, Takayuki Hoshina, Masato Ogawa, et al.
Plos One|May 26, 2023
Prevalence of psychological distress, quality of life, and satisfaction among patients and family members following comprehensive genomic profiling testing: Protocol of the Quality of life for Cancer genomics and Advanced Therapeutics (Q-CAT) studyMakoto Nishino, Maiko Fujimori, Takafumi Koyama, et al.
Molecular Biosystems|August 2, 2006
Chiral sensing using a blue fluorescent antibodyHana Matsushita, Noboru Yamamoto, Michael M Meijler, et al.
Japanese Journal of Clinical Oncology|April 19, 2017
Efficacy and safety of osimertinib in a Japanese compassionate use programYutaka Fujiwara, Yasushi Goto, Shintaro Kanda, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2007
Antibody-catalyzed anaerobic destruction of methamphetamineYang Xu, Mark S Hixon, Noboru Yamamoto, et al.
Japanese Journal of Clinical Oncology|August 21, 2009
Gender difference in treatment outcomes in patients with stage III non-small cell lung cancer receiving concurrent chemoradiotherapyIkuo Sekine, Minako Sumi, Yoshinori Ito, et al.
Lung Cancer (Amsterdam, Netherlands)|April 3, 2025
Real-world safety and effectiveness of entrectinib in Japanese patients with ROS1 gene fusion-positive, unresectable, advanced/recurrent non-small cell lung cancer: Post-marketing surveillanceTakashi Seto, Sayuri Nakane, Lyu Ji, et al.
Thoracic Cancer|August 15, 2025
Effects of Sarcopenia on the Outcomes and Safety of Chemoradiotherapy Followed by Durvalumab for the Treatment of Patients With Locally Advanced Non-Small Cell Lung CancerKentaro Tamura, Hidehito Horinouchi, Mototaka Miyake, et al.
Pageof 44

Showing results (71-80 of 437) with videos related to

Sort By:
Pageof 44
Investigational New Drugs|July 2, 2016
Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumorsHidenori Mizugaki, Noboru Yamamoto, Haruyasu Murakami, et al.
Japanese Journal of Clinical Oncology|October 22, 2014
A Phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small-cell lung cancer (JCOG1201)Junko Eba, Tsuneo Shimokawa, Kenichi Nakamura, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|September 20, 2020
The optimal duration of antimicrobial therapy for lower respiratory tract infection in patients with neuromuscular disorders based on a clone library analysis of the bacterial 16S rRNA gene sequenceMasaru Kawamura, Takayuki Hoshina, Masato Ogawa, et al.
Plos One|May 26, 2023
Prevalence of psychological distress, quality of life, and satisfaction among patients and family members following comprehensive genomic profiling testing: Protocol of the Quality of life for Cancer genomics and Advanced Therapeutics (Q-CAT) studyMakoto Nishino, Maiko Fujimori, Takafumi Koyama, et al.
Molecular Biosystems|August 2, 2006
Chiral sensing using a blue fluorescent antibodyHana Matsushita, Noboru Yamamoto, Michael M Meijler, et al.
Japanese Journal of Clinical Oncology|April 19, 2017
Efficacy and safety of osimertinib in a Japanese compassionate use programYutaka Fujiwara, Yasushi Goto, Shintaro Kanda, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2007
Antibody-catalyzed anaerobic destruction of methamphetamineYang Xu, Mark S Hixon, Noboru Yamamoto, et al.
Japanese Journal of Clinical Oncology|August 21, 2009
Gender difference in treatment outcomes in patients with stage III non-small cell lung cancer receiving concurrent chemoradiotherapyIkuo Sekine, Minako Sumi, Yoshinori Ito, et al.
Lung Cancer (Amsterdam, Netherlands)|April 3, 2025
Real-world safety and effectiveness of entrectinib in Japanese patients with ROS1 gene fusion-positive, unresectable, advanced/recurrent non-small cell lung cancer: Post-marketing surveillanceTakashi Seto, Sayuri Nakane, Lyu Ji, et al.
Thoracic Cancer|August 15, 2025
Effects of Sarcopenia on the Outcomes and Safety of Chemoradiotherapy Followed by Durvalumab for the Treatment of Patients With Locally Advanced Non-Small Cell Lung CancerKentaro Tamura, Hidehito Horinouchi, Mototaka Miyake, et al.
Pageof 44